一種新型設(shè)備被設(shè)計用于在外科手術(shù)切除時候的血管組織凝固。該設(shè)備已經(jīng)獲得了美國食品藥品管理局的許可，并獲得了CE標志。

HABIB4X切除設(shè)備是由Rita醫(yī)療系統(tǒng)公司研制開發(fā)的。該設(shè)備能夠凝固“外科手術(shù)切除平面”，從而能夠進行快速切開，而出血較少。該公司相信這種技術(shù)能夠用于肝臟癌癥手術(shù)，因為該設(shè)備被設(shè)計將手術(shù)過程中的出血和輸血降至最少。該設(shè)備被設(shè)計用于當前的Rita 1500X型發(fā)生器射頻消融工作平臺。

該設(shè)備具有下述特征：兩極電極設(shè)備，用于快速組織消融和凝固；自動Rita 1500X發(fā)生器軟件升級功能；外科組織切除手術(shù)時候出血最少；降低了手術(shù)、腫瘤學和癌癥領(lǐng)域的費用，包括現(xiàn)在的以及潛在的新客戶，這些都與切除方案密切相關(guān)。

Rita公司總裁和首席執(zhí)行官Joseph DeVivo說：“因為我們側(cè)重于癌癥治療，所以我們希望HABIB4X成為我們產(chǎn)品系列的一個強有力的補充。”

Resection Device for Cancer Surgery
 
A new device is designed for use in vascular tissue coagulation during surgical resection. The device has been cleared by the U.S. Food and Drug Administration (FDA) and has also received the CE Mark.

The HABIB4X resection device was developed by Rita Medical Systems, Inc. (Fremont, CA, USA). The device coagulates a “surgical resection plane” to facilitate a fast dissection with limited blood loss. The company believes this technology will be utilized in liver cancer surgeries since it is designed to minimize blood loss and blood transfusion during surgery. The device is designed to work on the current Rita radiofrequency ablation (RFA) platform of 1500X generators.

The device includes the following features: a bipolar electrode device designed for fast tissue ablation and coagulation, automatic operation with Rita 1500X generator software upgrade, minimized blood loss during surgical tissue resection, and reduced costs interest to the surgery, oncology, and cancer communities, which include existing as well as many potential new customers,” observed associated with resection procedures.

“With our focus on cancer therapies, we expect the HABIB4X to be a strong addition to our product portfolio and for it to be of Joseph DeVivo, president and CEO of Rita Medical Systems.